A 45-trial vitamin D meta-analysis does not justify taking it for cardiometabolic optimization

A 45-trial meta-analysis found a modest reduction in systolic blood pressure with vitamin D supplementation, but its apparent benefits for LDL cholesterol, fasting glucose, and HbA1c appeared only after the authors removed influential trials at high risk of bias. The practical decision is simple: do not start or increase vitamin D solely to optimize cardiometabolic markers.

Abumweis and colleagues pooled 45 randomized controlled trials comparing oral vitamin D with placebo in adults. The review searched PubMed, the Cochrane Library, and ClinicalTrials.gov, and was published in the August 2026 issue of Asia Pacific Journal of Clinical Nutrition. 1

The trials included both healthy adults and people with obesity, diabetes, hypertension, chronic kidney disease, polycystic ovary syndrome, metabolic syndrome, and other cardiometabolic conditions. Most used vitamin D3. Doses ranged from 20 to 100,000 IU, and interventions lasted 1 to 36 months. That spread is not a dosing protocol; it is a warning that the pooled estimate combines very different experiments. 2

The primary analysis asked whether the average change differed between vitamin D and placebo. The sensitivity analysis then removed influential studies whose results were far from the common pattern. Those two analyses do not tell the same story:

The distinction matters. A headline saying that vitamin D "reduced LDL, glucose, and HbA1c" compresses the review's most fragile results into a single sentence. In the main model, those three outcomes did not show a statistically significant average benefit. The paper's positive estimates came from a second pass that excluded studies judged influential or high risk of bias. 2

The signal was not uniform across participants. Adults aged 55 and older had lower LDL cholesterol by 0.142 mmol/L and lower systolic blood pressure by 3.150 mm Hg in subgroup analyses. Adults younger than 55 had lower fasting glucose by 0.142 mmol/L. Participants whose baseline 25-hydroxyvitamin D level was below 50 nmol/L had lower fasting glucose by 0.127 mmol/L and HbA1c by 0.252%. 2

Those findings help generate a better trial question: does baseline vitamin D status identify people who respond? They do not establish that a person can choose a dose from a blood-test threshold. The authors also say the subgroup analyses were not powered to prove that age or vitamin D status truly modifies the treatment effect. 2

Three problems limit what a reader can do with the pooled estimates.

First, the interventions were too different to yield a single useful regimen. The trials varied in dose, duration, baseline vitamin D status, body size, and health condition. The primary analysis had substantial heterogeneity for systolic blood pressure, fasting glucose, triglycerides, HDL cholesterol, and inflammatory markers. For example, I² was 82.6% for systolic blood pressure and 78.4% for fasting glucose, meaning that much of the variation came from differences between studies rather than one consistent effect. 2

Second, the trial reports were not uniformly strong. Allocation concealment was reported in about 30% of the included trials, around half were judged at high risk of performance bias, and about 70% had unclear risk of detection bias. The HbA1c funnel plot also showed asymmetry, which the authors interpret as possible publication bias. 2

Third, the review measured risk markers, not fewer heart attacks, strokes, or new cases of diabetes. A change of a few units in a laboratory marker can be biologically interesting without proving a meaningful change in how long people live or how often they develop cardiovascular disease. The authors explicitly say that the clinical relevance of these modest changes remains uncertain. 1

Do not add vitamin D, or raise your dose, just to lower LDL cholesterol, blood pressure, fasting glucose, or HbA1c. This meta-analysis does not identify a reliable prevention dose, and its most favorable lipid and glucose estimates depended on excluding influential trials. The study used doses as high as 100,000 IU, but that does not make a high dose appropriate for home use.

If you already have a clinician-directed vitamin D plan for deficiency or another medical indication, this paper is not a reason to change it. Ask what the treatment is meant to accomplish and whether your follow-up should use a blood vitamin D measurement, a disease marker, or both. For dietitians, the useful distinction is between correcting a documented problem and taking a supplement in the hope that a small average marker change will prevent cardiovascular disease.

The study was funded by Hashemite University in Jordan. Stephanie Jew disclosed that she is a federal public servant and that the opinions in the paper are not those of the Government of Canada; the other authors declared no conflicts of interest. 2

The actionable takeaway is therefore restraint: make no new vitamin D supplement change on the basis of this meta-analysis alone. Use a clinician-guided plan when there is a documented indication, and do not treat the paper's most favorable sensitivity estimates as a general cardiometabolic prescription.